

If more than one search is submitted, please prioritize searches in order of need.

Title of Invention: _____

Inventors (please provide full names): See attached Bib sheet

Earliest Priority Filing Date: 4/25/2000

Virgin? Please search claims
 1-25
 attached claims and abstracts

Full Search Including authors
and meetings

Point of Contact:
Mary Hale
Technical Info. Specialist
CM1 12D16 Tel: 303-4258

return the attached
Search.

authors
 cells
 maiden dark
 African green monkey kidney
 canine monocyte
 mouse
 papers with
 fetal rhesus monkey kidney
 feline kidney
 baby hamster kidney

Searcher: [Signature]

Searcher Phone #: _____

Searcher Location: _____

Date Searcher Picked Up: _____

Date Completed: 8/20

Searcher Prep & Review Time:

NA Sequence (#) _____

AA Sequence (#)_____

Structure (#) _____

Bibliographic

Litigation _____

Fulltext

STN 106.150

Dialog _____

Questel/Orbit _____

Dr. Link _____

Lexis/Nexis

Sequence Systems

K. S-Shah
840485

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY	SESSION
	-7.06	-26.46

FILE 'CAPLUS' ENTERED AT 10:56:39 ON 30 AUG 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1947 - 30 Aug 2001 VOL 135 ISS 10
FILE LAST UPDATED: 29 Aug 2001 (20010829/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

CAPLUS now provides online access to patents and literature covered in CA from 1947 to the present. On April 22, 2001, bibliographic information and abstracts were added for over 2.2 million references published in CA from 1947 to 1966.

The CA Lexicon is now available in the Controlled Term (/CT) field. Enter HELP LEXICON for full details.

Attention, the CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

E#	FREQUENCY	AT	TERM
--	-----	--	----
E1	0	1	MEROTERPENOID/CT
E2	0	3	MEROTERPENOID QUINONES/CT
E3	0	2 -->	MEROZOITE/CT
E4	0	2	MEROZOITE SURFACE PROTEIN 1/CT
E5	0	1	MERPIQUAT/CT

=> e e3+all/ct

E1 0 --> Merozoite/CT
E2 USE Development, microbial (L) merozoite/CT
***** END***

=> e sarcocystis neurona/ct 5

E#	FREQUENCY	AT	TERM
E1	1	5	SARCOCYSTIS MUCOSA/CT
E2	18	5	SARCOCYSTIS MURIS/CT
E3	31	5 -->	SARCOCYSTIS NEURONA/CT
E4	1		SARCOCYSTIS OVICANIS/CT
E5	3	5	SARCOCYSTIS OVIFELIS/CT

=> e e3+all/ct

E1	2314	BT4	Eukaryote (Eukaryotae)/CT
E2	75	BT3	Apicomplexa/CT
E3	74	BT2	Coccidia/CT
E4	46	BT1	Sarcocystis/CT
E5	31	-->	Sarcocystis neurona/CT

HN Valid heading during volume 116 (1992) to present.

***** END***

=> s e4-5

	46	SARCOCYSTIS/CT
	31	"SARCOCYSTIS NEURONA"/CT
L1	71	(SARCOCYSTIS/CT OR "SARCOCYSTIS NEURONA"/CT)

=> e tachyzoite/ct 5

E#	FREQUENCY	AT	TERM
E1	3	11	TACHYSURUS THALASSINUS/CT
E2	2	11	TACHYSURUS ZONA/CT
E3	0	-->	TACHYZOITE/CT
E4	1		TACITUS BELLUS/CT
E5	0	1	TACKACE/CT

=> e neospora hughesi/ct

E#	FREQUENCY	AT	TERM
E1	30	6	NEOSPORA/CT
E2	97	5	NEOSPORA CANINUM/CT
E3	6	5 -->	NEOSPORA HUGHESI/CT
E4	0	8	NEOSTENANTHERA/CT
E5	1	8	NEOSTENANTHERA GABONENSIS/CT
E6	0	13	NEOSTIGMINE/CT
E7	0	8	NEOSTREARIA/CT
E8	1	8	NEOSTREARIA FLECKERI/CT
E9	368	2	NEOSTRIATUM/CT
E10	0	2	NEOSTRIATUM (L) DOPAMINERGIC SYSTEM/CT
E11	0	2	NEOSTRIATUM BRAIN/CT
E12	0	2	NEOSTRIATUM, DOPAMINERGIC SYSTEM BRAIN/CT

=> e e3+all/ct

E1	2314	BT4	Eukaryote (Eukaryotae)/CT
E2	75	BT3	Apicomplexa/CT
E3	74	BT2	Coccidia/CT
E4	30	BT1	Neospora/CT
E5	6	-->	Neospora hughesi/CT

***** END***

=> s e5

L2 6 "NEOSPORA HUGHESI"/CT

=> e protozoicidal/ct 5

E#	FREQUENCY	AT	TERM
E1	0	2	PROTOZOAL INFECTION (L) SLEEPING SICKNESS/CT
E2	0	2	PROTOZOAN/CT
E3	0	-->	PROTOZOCIDAL/CT
E4	0	12	PROTRACHEONISCUS/CT
E5	2	12	PROTRACHEONISCUS ORIENTALIS/CT

=> e epm/ct 5

E#	FREQUENCY	AT	TERM
E1	0	2	EPK/CT
E2	0	1	EPL/CT
E3	0	1	--> EPM/CT
E4	0	2	EPM 4050/CT
E5	0	2	EPM 4060N/CT

=> e e3+all/ct

E1 0 --> EPM/CT

***** END***

=> e equine protozoal myeloencephal?/ct 5

E#	FREQUENCY	AT	TERM
E1	0	2	EQUINE MORBILLIVIRUS/CT
E2	2	7	EQUINE PAPILLOMAVIRUS/CT
E3	0	-->	EQUINE PROTOZOAL MYELOENCEPHAL?/CT
E4	2	6	EQUINE RHINOVIRUS/CT
E5	1	6	EQUINE RHINOVIRUS 1/CT

=> e immune response/ct 5

E#	FREQUENCY	AT	TERM
E1	0	31	IMMUNE PROCESSES AND PHENOMENA (NON-CA HEADING)/CT
E2	0	65	IMMUNE RECEPTORS (NON-CA HEADING)/CT
E3	0	2	--> IMMUNE RESPONSE/CT
E4	0	2	IMMUNE SERUMS/CT
E5	0	2	IMMUNE SUPPRESSANTS/CT

=> e e3+all/ct

E1 0 --> Immune response/CT

E2 23219 USE Immunity/CT

***** END***

=> s e2

L3 23219 IMMUNITY/CT

=> e equine dermal/ct 5

E#	FREQUENCY	AT	TERM
--	-----	--	----

E1	0	2	EQUINE CHORIONIC GONADOTROPIN/CT
E2	1		EQUINE CORONAVIRUS/CT
E3	0	-->	EQUINE DERMAL/CT
E4	1	5	EQUINE FOAMY VIRUS/CT
E5	0	2	EQUINE HERPES 5 VIRUS/CT

=> e maiden darby bovine/ct

E#	FREQUENCY	AT	TERM
--	-----	--	----
E1	1	6	MAIASAURA PEEBLESORUM/CT
E2	0	1	MAICHUON/CT
E3	0	-->	MAIDEN DARBY BOVINE/CT
E4	0	1	MAIDENHAIR/CT
E5	0	2	MAIDENHAIR TREE/CT
E6	0	1	MAIDENI/CT
E7	0	1	MAIDENII/CT
E8	0	1	MAIDIDUS/CT
E9	0	1	MAIDIRADICIS/CT
E10	0	1	MAIDIS/CT
E11	0	2	MAIDISM/CT
E12	0	2	MAIDS/CT

=> fil medli

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	8.17	432.50
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-26.46

FILE 'MEDLINE' ENTERED AT 10:59:53 ON 30 AUG 2001

FILE LAST UPDATED: 28 AUG 2001 (20010828/UP). FILE COVERS 1958 TO DATE.

On April 22, 2001, MEDLINE was reloaded. See HELP RLOAD for details.

MEDLINE now contains IN-PROCESS records. See HELP CONTENT for details.

MEDLINE is now updated 4 times per week. A new current-awareness alert frequency (EVERYUPDATE) is available. See HELP UPDATE for more information.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2001 vocabulary. Enter HELP THESAURUS for details.

The OLDMEDLINE file segment now contains data from 1958 through 1965. Enter HELP CONTENT for details.

Left, right, and simultaneous left and right truncation are available in the Basic Index. See HELP SFIELDS for details.

THIS FILE CONTAINS CAS REGISTRY NUMBERS FOR EASY AND ACCURATE SUBSTANCE IDENTIFICATION.

=> e maiden darby bovine/ct

E#	FREQUENCY	AT	TERM
---	-----	---	----
E1	0	2	MAI INFECT/CT
E2	0	2	MAIC/CT
E3	0	-->	MAIDEN DARBY BOVINE/CT
E4	0	1	MAIDENHAIR/CT
E5	0	2	MAIDENHAIR TREE/CT
E6	0	2	MAIDS/CT
E7	0	2	MAIL/CT
E8	0	2	MAIL DISTRIBUTION/CT
E9	0	2	MAIL DISTRIBUTIONS/CT
E10	0	2	MAIL ORDER/CT
E11	0	2	MAIL, ELECTRONIC/CT
E12	0	2	MAIL-ORDER/CT

=> e equine dermal/ct 5

E#	FREQUENCY	AT	TERM
---	-----	---	----
E1	0	2	EQUINE ARTERITIS VIRUSES/CT
E2	0	2	EQUINE COITAL EXANTHEMA VIRUS/CT
E3	0	-->	EQUINE DERMAL/CT
E4	0	2	EQUINE DISEASE/CT
E5	0	2	EQUINE DISEASES/CT

=> e canine monocyte/ct 5

E#	FREQUENCY	AT	TERM
---	-----	---	----
E1	0	2	CANINE INFECTIOUS HEPATITIS/CT
E2	0	2	CANINE INFECTIOUS HEPATITIS VIRUS/CT
E3	0	-->	CANINE MONOCYTE/CT
E4	0	2	CANINE PARVOVIRUS/CT
E5	0	2	CANINE PARVOVIRUSES/CT

=> e mouse monocyte/ct 5

E#	FREQUENCY	AT	TERM
---	-----	---	----
E1	0	2	MOUSE LYMPHOCYTE PROTEIN MOIETY REDUCED OF INTERFERON
E2	0	2	TYPE II/CT MOUSE MAMMARY TUMOR VIRUS/CT
E3	0	-->	MOUSE MONOCYTE/CT
E4	0	2	MOUSE MUTANT STRAIN/CT
E5	0	2	MOUSE MUTANT STRAINS/CT

=> e fetal rhesus monkey kidney/ct 5

E#	FREQUENCY	AT	TERM
---	-----	---	----
E1	40		FETAL RESORPTION: VE, VETERINARY/CT
E2	0	2	FETAL RESORPTIONS/CT
E3	0	-->	FETAL RHESUS MONKEY KIDNEY/CT
E4	0	2	FETAL STRUCTURE/CT
E5	0	2	FETAL STRUCTURES/CT

=> e feline kidney/ct 5

E#	FREQUENCY	AT	TERM
----	-----------	----	------

```

--      -----      --      ----
E1          7          FELINE INFECTIOUS PERITONITIS: TM, TRANSMISSION/CT
E2         16          FELINE INFECTIOUS PERITONITIS: VI, VIROLOGY/CT
E3          0      --> FELINE KIDNEY/CT
E4          0          2          FELINE LENTIVIRUS/CT
E5          0          2          FELINE LENTIVIRUSES/CT

```

=> fil medl,caplus,biosis,embase,wpids,jicst
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.60	433.10

	SINCE FILE ENTRY	TOTAL SESSION
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)		
CA SUBSCRIBER PRICE	0.00	-26.46

FILE 'MEDLINE' ENTERED AT 11:01:09 ON 30 AUG 2001

FILE 'CAPLUS' ENTERED AT 11:01:09 ON 30 AUG 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 11:01:09 ON 30 AUG 2001
COPYRIGHT (C) 2001 BIOSIS(R)

FILE 'EMBASE' ENTERED AT 11:01:09 ON 30 AUG 2001
COPYRIGHT (C) 2001 Elsevier Science B.V. All rights reserved.

FILE 'WPIDS' ENTERED AT 11:01:09 ON 30 AUG 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'JICST-EPLUS' ENTERED AT 11:01:09 ON 30 AUG 2001
COPYRIGHT (C) 2001 Japan Science and Technology Corporation (JST)

=> s (l1 or l2 or merozoite? or sarcocystis neurona or tachyzoite or neospor?
hughes? or protozocid?)

```

L4          3707 FILE MEDLINE
L5          1804 FILE CAPLUS
L6          3473 FILE BIOSIS
L7          2743 FILE EMBASE
L8           108 FILE WPIDS
L9           179 FILE JICST-EPLUS

```

TOTAL FOR ALL FILES

```

L10         12014 (L1 OR L2 OR MEROZOITE? OR SARCOCYSTIS NEURONA OR TACHYZOITE
OR
              NEOSPOR? HUGHES? OR PROTOZOCID?)

```

=> s (epm or equine protozoa? myeloencephal?)

```

L11          376 FILE MEDLINE
L12          856 FILE CAPLUS
L13          472 FILE BIOSIS
L14          332 FILE EMBASE
L15          380 FILE WPIDS

```

L16 75 FILE JICST-EPLUS

TOTAL FOR ALL FILES

L17 2491 (EPM OR EQUINE PROTOZOA? MYELOENCEPHAL?)

=> s (equine derma? or maiden darby (w)(canine or bovine)(w)kidney or african green monkey kidney or (canine or mouse)(w)monocyte or fetal rhesus monkey kidney or feline kidney or baby hamster kidney)(2a)cell!

L18 1449 FILE MEDLINE

L19 1645 FILE CAPLUS

L20 6592 FILE BIOSIS

L21 1282 FILE EMBASE

L22 75 FILE WPIDS

L23 39 FILE JICST-EPLUS

TOTAL FOR ALL FILES

L24 11082 (EQUINE DERMA? OR MAIDEN DARBY (W)(CANINE OR BOVINE)(W) KIDNEY OR AFRICAN GREEN MONKEY KIDNEY OR (CANINE OR MOUSE)(W)

MONOCYTE

OR FETAL RHESUS MONKEY KIDNEY OR FELINE KIDNEY OR BABY HAMSTER KIDNEY)(2A) CELL!

=> s l10 and l17 and l24

L25 1 FILE MEDLINE

L26 0 FILE CAPLUS

L27 1 FILE BIOSIS

L28 1 FILE EMBASE

L29 1 FILE WPIDS

L30 0 FILE JICST-EPLUS

TOTAL FOR ALL FILES

L31 4 L10 AND L17 AND L24

=> dup rem l31

PROCESSING COMPLETED FOR L31

L32 2 DUP REM L31 (2 DUPLICATES REMOVED)

=> d cbib abs 1-2

L32 ANSWER 1 OF 2 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD

AN 2000-571969 [53] WPIDS

CR 2001-218486 [22]

AB ~~WO-200049049~~ A UPAB: 20010421 ✓

NOVELTY - Detection of **Sarcocystis neurona** in horses by identifying a specific antibody-antigen complex via an immunoassay is new.

DETAILED DESCRIPTION - Detection of **Sarcocystis neurona** in an equine in an immunoassay is improved by reacting a biological sample from the horse suspected of harboring the *S. neurona* with an antibody (Ab) which is selective in binding to an identifying *S. neurona* antigen (Ag) to form an Ab-Ag complex.

INDEPENDENT CLAIMS are also included for the following:

(1) a kit for detecting *S. neurona* in a biological sample from an equine;

(2) monoclonal antibodies against 16 plus or minus 4 kDa or 30 plus

or minus 4 kDa antigens of *S. neurona*; and
 (3) isolated DNA sequences encoding the 16 plus or minus 4 kDa and
 30 plus or minus 4 kDa antigens of *S. neurona*.
 USE - The methods and antibodies are useful for detecting *S. neurona*
 (claimed) which causes **equine protozoal**
myeloencephalitis, a neurological disorder in horses.
 Dwg.0/0

L32 ANSWER 2 OF 2 MEDLINE DUPLICATE 1
 2000043702 Document Number: 20043702. PubMed ID: 10577742. Simplified
 technique for isolation, excystation, and culture of *Sarcocystis* species
 from opossums. Murphy A J; Mansfield L S. (Animal Health Diagnostic
 Laboratory, Michigan State University, East Lansing 48824, USA.) (JOURNAL
 OF PARASITOLOGY, (1999 Oct). 85 (5) 979-81. Journal code: JL3; 7803124.
 ISSN: 0022-3395. Pub. country: United States. Language: English.
 AB ***Sarcocystis neurona*** is a protozoan parasite that
 causes a neurological disease in horses called **equine**
protozoal myeloencephalitis. The route of transmission
 is speculated to be by fecal-oral transfer of sporocysts shed from
 opossums. Controversy exists regarding both the natural life cycle for
 this parasite as well as the species identity of opossum *Sarcocystis*. To
 provide stage-specific material for species comparison, 27 opossums from
 southern Michigan were screened for *Sarcocystis* spp. sporocysts. Seven
 opossums were positive for *Sarcocystis* sporocysts by fecal flotation. A
 simplified, effective technique for isolation, excystation, and culture
 of opossum *Sarcocystis* sp. from mucosal scrapings was developed. All 7
Sarcocystis sp. isolates were successfully cultured to grow long term in
equine dermal cells to the **merozoite**
 stage. **Merozoites** were observed between 5 and 15 days after
 inoculation. In conclusion, opossums shed *Sarcocystis* sp. sporocysts that
 may be manipulated to excyst and grow in vitro in equine dermal cell
 lines to the **merozoite** stage using the simplified technique described.

=> s l10 and l17 and (l3 or immunity or immune response or immunogen?)

L33 5 FILE MEDLINE
 L34 3 FILE CAPLUS
 L35 3 FILE BIOSIS
 L36 4 FILE EMBASE
 L37 1 FILE WPIDS
 L38 0 FILE JICST-EPLUS

TOTAL FOR ALL FILES

L39 16 L10 AND L17 AND (L3 OR IMMUNITY OR IMMUNE RESPONSE OR
 IMMUNOGEN?
)

=> s l39 not l31

L40 5 FILE MEDLINE
 L41 3 FILE CAPLUS
 L42 3 FILE BIOSIS
 L43 4 FILE EMBASE

L44 1 FILE WPIDS
L45 0 FILE JICST-EPLUS

TOTAL FOR ALL FILES

L46 16 L39 NOT L31

=> dup rem l46

PROCESSING COMPLETED FOR L46

L47 8 DUP REM L46 (8 DUPLICATES REMOVED)

=> d cbib abs 1-8

L47 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2001 ACS

2001:167817 Document No. 134:221431 Vaccine to control **equine protozoal myeloencephalitis** in horses. Mansfield, Linda S.; Rossano, Mary G.; Murphy, Alice J.; Vrable, Ruth A. (Michigan State University, USA). PCT Int. Appl. WO 2001015708 A1 20010308, 57 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA,

CH,

CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2000-US24221 20000831. PRIORITY: US 1999-PV152193 19990902; US 2000-513086 20000224.

AB The present invention provides vaccines and methods for making the vaccines that actively or passively protect an equid or other animal against **Sarcocystis neurona**. In particular, the present invention provides vaccines that provide active **immunity** which comprise a polypeptide or DNA vaccine that contains or expresses at least one epitope of an antigen that has an amino acid sequence substantially similar to a unique 16 (+/-4) kDa antigen and/or 30 (+/-4) kDa antigen of **Sarcocystis neurona**. The present invention further provides a vaccine that provides passive **immunity** to **Sarcocystis neurona** comprising polyclonal or monoclonal antibodies against at least one epitope of an antigen substantially similar to a unique 16 (+/-4) kDa antigen and/or 30 (+/-4) kDa antigen of **Sarcocystis neurona**.

L47 ANSWER 2 OF 8 MEDLINE DUPLICATE 1
2001434376 Document Number: 21125368. PubMed ID: 11226451. Molecular comparison of the dense granule proteins GRA6 and GRA7 of **Neospora hughesi** and *Neospora caninum*. Walsh C P; Vemulapalli R; Sriranganathan N; Zajac A M; Jenkins M C; Lindsay D S. (Center for Molecular Medicine and Infectious Diseases, Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Blacksburg, VA 24061-0342, USA.) INTERNATIONAL JOURNAL FOR PARASITOLOGY, (2001 Mar) 31 (3) 253-8. Journal code: GSB; 0314024. ISSN: 0020-7519. Pub. country: England: United Kingdom.

Language:

English.

AB **Neospora hughesi** is a recently described apicomplexan parasite that has been associated with several cases of **equine**

protozoal myeloencephalitis. The biology of this new parasite is just beginning to be defined. Towards this understanding, we report important differences between the nucleotide and deduced amino acid sequences of the dense granule proteins GRA6 and GRA7 of *N. hughesi* and *Neospora caninum*. This information can be used to differentiate the two species and contribute to further understanding of the prevalence and biology of *N. hughesi*. The newly defined proteins of *N. hughesi* are referred to as NhGRA6 and NhGRA7 in keeping with the protocol for naming homologous proteins of the Apicomplexa. Genes of the two dense granule proteins of *N. hughesi* (isolate Nh-A1) and four different isolates of *N. caninum* were isolated via PCR and their DNA sequences were determined. Computer analysis indicated that the two gene sequences were identical among all four *N. caninum* isolates. However, the gene for NhGRA6 was found to be 96 nucleotides longer at the 3' end than that of NcGRA6, resulting in a protein product that is 32 amino acids larger than NcGRA6. Two tandem repeat sequences were identified at the 3' end of the NhGRA6 gene. These repeat sequences contributed to the lengthening of the carboxy terminus of NhGRA6 in comparison with that of NcGRA6. The larger size of NhGRA6 was further confirmed by Western blot analysis in which NcGRA6 monospecific antibodies recognised a protein of approximately 42 kDa in *N. hughesi* whole **tachyzoite** preparation but a protein of 37 kDa in *N. caninum* whole **tachyzoite** preparation. Analysis of GRA7 gene sequences indicated a 6 and 14.8% difference at nucleotide and amino acid sequence level, respectively, between NcGRA7 and NhGRA7. Despite the same number of residues in the deduced amino acid sequences of all the GRA7 proteins, Western blot analysis indicated a difference in the migration pattern of NhGRA7 in comparison with NcGRA7. Results of our study indicate that diagnostic tests based on differences in dense granule sequences and antigenicity may have potential to differentiate between *N. hughesi* and *N. caninum*. Such diagnostic tests would be valuable tools to aid in our understanding of the epidemiology of these parasites. Additionally, dense granule proteins are **immunogenic** and they may have potential as use in recombinant vaccines against neosporosis.

L47 ANSWER 3 OF 8 MEDLINE DUPLICATE 2
 2001354018 Document Number: 21127318. PubMed ID: 11223200.
 Immunoconversion against **Sarcocystis neurona** in normal and dexamethasone-treated horses challenged with *S. neurona* sporocysts. Cutler T J; MacKay R J; Ginn P E; Gillis K; Tanhauser S M; LeRay E V; Dame J B; Greiner E C. (Department of Pathobiology, PO Box 100880, College of Veterinary Medicine, University of Florida, Gainesville 32610, USA.) VETERINARY PARASITOLOGY, (2001 Feb 26) 95 (2-4) 197-210. Journal code: XBU; 7602745. ISSN: 0304-4017. ~~Pub. country: Netherlands. Language: English.~~
 AB **Equine protozoal myeloencephalitis** is a common neurologic disease of horses in the Americas usually caused by **Sarcocystis neurona**. To date, the disease has not been induced in horses using characterized sporocysts from *Didelphis*

virginiana, the definitive host. *S. neurona* sporocysts from 15 naturally infected opossums were fed to horses seronegative for antibodies against *S. neurona*. Eight horses were given 5×10^5 sporocysts daily for 7 days. Horses were examined for abnormal clinical signs, and blood and cerebrospinal fluid were harvested at intervals for 90 days after the first day of challenge and analyzed both qualitatively (western blot) and quantitatively (anti-17kDa) for anti-*S. neurona* IgG. Four of the challenged horses were given dexamethasone (0.1mg/kg orally once daily) for the duration of the experiment. All challenged horses immunoconverted against *S. neurona* in blood within 32 days of challenge and in CSF within 61 days. There was a trend ($P = 0.057$) for horses given dexamethasone to immunoconvert earlier than horses that were not immunosuppressed. Anti-17kDa was detected in the CSF of all challenged horses by day 61. This response was statistically greater at day 32 in horses given dexamethasone. Control horses remained seronegative throughout the period in which all challenged horses converted. One control horse immunoconverted in blood at day 75 and in CSF at day 89. Signs of neurologic disease were mild to equivocal in challenged horses. Horses given dexamethasone had more severe signs of limb weakness than did horses

not given dexamethasone; however, we could not determine whether these signs were due to spinal cord disease or to effects of systemic illness. At necropsy, mild-moderate multifocal gliosis and neurophagia were found histologically in the spinal cords of 7/8 challenged horses. No organisms were seen either in routinely processed sections or by immunohistochemistry. Although neurologic disease comparable to naturally occurring **equine protozoal myeloencephalitis (EPM)** was not produced, we had clear evidence of an **immune response** to challenge both systemically and in the CNS. Broad immunosuppression with dexamethasone did not increase the severity of histologic changes in the CNS of challenged horses. Future work must focus on defining the factors that govern progression of inapparent *S. neurona* infection to **EPM**.

L47 ANSWER 4 OF 8 MEDLINE
2001354017 Document Number: 21127317. PubMed ID: 11223199.

Interpretation

of the detection of **Sarcocystis neurona** antibodies in the serum of young horses. Cook A G; Buechner-Maxwell V; Morrow J K; Ward D L; Parker N A; Dascanio J J; Ley W B; Cooper W. (Department of Large Animal Clinical Sciences, Virginia-Maryland College of Veterinary Medicine, Duck Pond Drive Phase II, Blacksburg, VA 24061, USA.. ancook2@vt.edu) . VETERINARY PARASITOLOGY, (2001 Feb 26) 95 (2-4) 187-95. Journal code: XBU; 7602745. ISSN: 0304-4017. Pub. country: Netherlands. Language: English.

AB Horses that are exposed to **Sarcocystis neurona**, a causative agent of **equine protozoal myeloencephalitis**, produce antibodies that are detectable in serum by western blot (WB). A positive test is indicative of exposure to the organism. Positive tests in young horses can be complicated by the presence of maternal antibodies. Passive transfer of maternal antibodies to *S. neurona* from seropositive mares to their foals was evaluated. Foals were sampled at birth (presuckle), at 24h of age (postsuckle), and at monthly intervals. All foals sampled before suckling were seronegative. Thirty-three foals from 33 seropositive mares became seropositive with

colostrum ingestion at 24h of age, confirming that passive transfer of S. neurona maternal antibodies occurs. Thirty-one of the 33 foals became seronegative by 9 months of age, with a mean seronegative conversion time of 4.2 months. These results indicate that evaluation of exposure to S. neurona by WB analysis of serum may be misleading in young horses.

L47 ANSWER 5 OF 8 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.

2001075066 EMBASE A review of **Sarcocystis neurona** and

equine protozoal myeloencephalitis (

EPM). Dubey J.P.; Lindsay D.S.; Saville W.J.A.; Reed S.M.;

Granstrom D.E.; Speer C.A.. J.P. Dubey, United States Dept. of

Agriculture, Animal and Natural Resources Inst., Beltsville Agricultural Res. Center, Beltsville, MD 20705-2350, United States.

jdubey@anri.barc.usda.gov. Veterinary Parasitology 95/2-4 (89-131) 26 Feb 2001.

Refs: 148.

ISSN: 0304-4017. CODEN: VPARDI.

Publisher Ident.: S 0304-4017(00)00384-8. Pub. Country: Netherlands.

Language: English. Summary Language: English.

AB **Equine protozoal myeloencephalitis** (

EPM) is a serious neurological disease of horses in the Americas.

The protozoan most commonly associated with **EPM** is

Sarcocystis neurona. The complete life cycle of S.

neurona is unknown, including its natural intermediate host that harbors

its sarcocyst. Opossums (*Didelphis virginiana*, *Didelphis albiventris*) are

its definitive hosts. Horses are considered its aberrant hosts because

only schizonts and **merozoites** (no sarcocysts) are found in

horses. **EPM**-like disease occurs in a variety of mammals

including cats, mink, raccoons, skunks, Pacific harbor seals, ponies, and

Southern sea otters. Cats can act as an experimental intermediate host

harboring the sarcocyst stage after ingesting sporocysts. This paper

reviews information on the history, structure, life cycle, biology,

pathogenesis, induction of disease in animals, clinical signs, diagnosis,

pathology, epidemiology, and treatment of **EPM** caused by S.

neurona.

L47 ANSWER 6 OF 8 MEDLINE

2001156688 Document Number: 21088454. PubMed ID: 11219340. **Equine**

protozoal myeloencephalitis. MacKay R J; Granstrom D E;

Saville W J; Reed S M. (Department of Large Animal Clinical Sciences,

College of Veterinary Medicine, University of Florida, Gainesville,

Florida, USA.) VETERINARY CLINICS OF NORTH AMERICA. EQUINE PRACTICE,

(2000 Dec) 16 (3) 405-25. Ref: 96. Journal code: CEP; 8511904. ISSN:

0749-0739. Pub. country: United States. Language: English.

AB Recent advances in the understanding of the parasite life cycle, epidemiology, clinical signs, diagnosis, treatment, and prevention of

EPM are reviewed. The NAHMS Equine '98 study and a controlled

retrospective study from The Ohio State University College of Veterinary

Medicine identified a number of risk factors associated with development

of the disease. The national annual incidence of **EPM** was 1% or

less depending on the primary use of the animals. Increased disease risk

was associated with age (1-5 and > 13 years of age), season (lowest in

winter months and increasing with ambient temperature), previous

stressful

events, the presence of opossums, the use of nonsurface water drinking

systems, and failure to restrict wildlife access to feed. Horses that received treatment were 10 times more likely to improve, and those that improved were 50 times more likely to survive. A number of recent studies confirmed that horses can be experimentally infected with *S. neurona*; however, large numbers of sporocysts are apparently necessary to achieve infection, and clinical signs and abnormal CNS histology are only seen inconsistently. Results suggest that CNS infection and positive CSF immunoblot findings may be transient phenomena among naturally infected horses. Although immunosuppression may be involved in the development of **EPM**, some element of the **immune response** seems to be necessary for the development of clinical signs. Use of the standard immunoblot test for the detection of anti-*S. neurona* antibodies in CSF continues to provide the most useful adjunct to a detailed neurologic examination for the diagnosis of **EPM**. Test sensitivity and specificity were 89% in 295 horses euthanatized because of neurologic disease, of which 123 were confirmed cases of **EPM**. The PPV was 85%, and the NVP was 92%. A number of promising new **EPM** treatments are under investigation. In addition to standard SDZ/PYR therapy, toltrazuril, ponazuril, diclazuril, and NTZ have shown promise as possible alternatives.

L47 ANSWER 7 OF 8 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD

AN 1999-571872 [48] WPIDS

AB WO 9947927 A UPAB: 19991122

NOVELTY - Biologically pure culture of equine *Neospora*, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

- (a) detecting antibodies (Ab) specifically reactive with equine *Neospora* antigens (Ag) by forming an Ab-Ag complex;
- (b) detecting *Neospora* by forming a complex with an antibody (Ab1) specifically reactive with *Neospora* antigen;
- (c) detecting *Neospora*-specific nucleic acid (I) by hybridization with a specific oligonucleotide probe; and
- (d) pharmaceutical composition containing equine *Neospora* **immunogen** and a carrier.

ACTIVITY - Antiprotozoal.

MECHANISM OF ACTION - Induction of a specific **immune response**.

USE - **Immunogens** (optionally expressed from gene therapy vectors) from equine *Neospora* are used in vaccines for treatment or prevention of *Neospora* infection in horses and other animals. *Neospora* is a causative agent of **equine protozoal myeloencephalitis (EPM)**. Detection of *Neospora*-specific antigens, antibodies or nucleic acid (by usual immunoassay or hybridization tests) is used to diagnose infection. Antibodies (Ab) specific for equine *Neospora* are used for diagnosis; to select candidate **immunogens** for vaccine development; to isolate proteins; to screen DNA libraries and as therapeutic/prophylactic agents.

ADVANTAGE - Reagents specific for equine *Neospora* allow differentiation between **equine protozoal myeloencephalitis** caused by *Neospora* and **Sarcocystis neurona**. These pathogens require different treatments and treatment of *Neospora* is only effective if applied before the parasite

has

formed cysts. The vaccines also prevent shedding of oocysts by animals known to be infected.
Dwg.0/2

L47 ANSWER 8 OF 8 MEDLINE DUPLICATE 3
1998234002 Document Number: 98234002. PubMed ID: 9573058. Evidence that surface proteins Sn14 and Sn16 of **Sarcocystis neurona** **merozoites** are involved in infection and **immunity**. Liang F T; Granstrom D E; Zhao X M; Timoney J F. (Gluck Equine Research Center, Department of Veterinary Science, University of Kentucky, Lexington 40546-0099, USA.) **INFECTION AND IMMUNITY**, (1998 May) 66 (5) 1834-8. ✓
Journal code: GO7; 0246127. ISSN: 0019-9567. Pub. country: United States. Language: English.

AB **Sarcocystis neurona** is the etiologic agent of **equine protozoal myeloencephalitis (EPM)**. Based on an analysis of 25,000 equine serum and cerebrospinal fluid (CSF) samples, including samples from horses with neurologic signs typical of **EPM** or with histologically or parasitologically confirmed **EPM**, four major immunoblot band patterns have been identified. Twenty-three serum and CSF samples representing each of the four immunoblot patterns were selected from 220 samples from horses with neurologic signs resembling **EPM** and examined for inhibitory effects on the infectivity of *S. neurona* by an in vitro neutralization assay. A high correlation between immunoblot band pattern and neutralizing activity was detected. Two proteins, Sn14 and Sn16 (14 and 16 kDa, respectively), appeared to be important for in vitro infection. A combination of the results of surface protein labeling, immunoprecipitation, Western blotting, and trypsin digestion suggests that these molecules are surface proteins and may be useful components of a vaccine against *S. neurona* infection. Although *S. neurona* is an obligate intracellular parasite, it is potentially a target for specific antibodies which may lyse **merozoites** via complement or inhibit their attachment and penetration to host cells.

=> s bigbie, r?/au,in or bigbie r?/au,in;s ng, t?/au,in or ng t?/auin;s
whalen, j?/au,in or whalen j?/au,in

'IN' IS NOT A VALID FIELD CODE

L48 2 FILE MEDLINE

L49 0 FILE CAPLUS

L50 2 FILE BIOSIS

'IN' IS NOT A VALID FIELD CODE

L51 0 FILE EMBASE

L52 0 FILE WPIDS

L53 0 FILE JICST-EPLUS

TOTAL FOR ALL FILES

L54 4 BIGBIE, R?/AU,IN OR BIGBIE R?/AU,IN

'IN' IS NOT A VALID FIELD CODE

'AUIN' IS NOT A VALID FIELD CODE

L55 584 FILE MEDLINE

'AUIN' IS NOT A VALID FIELD CODE
 L56 620 FILE CAPLUS
 'AUIN' IS NOT A VALID FIELD CODE
 L57 746 FILE BIOSIS
 'IN' IS NOT A VALID FIELD CODE
 'AUIN' IS NOT A VALID FIELD CODE
 L58 509 FILE EMBASE
 'AUIN' IS NOT A VALID FIELD CODE
 L59 62 FILE WPIDS
 'AUIN' IS NOT A VALID FIELD CODE
 L60 6 FILE JICST-EPLUS

TOTAL FOR ALL FILES
 L61 2527 NG, T?/AU, IN OR NG T?/AUIN

'IN' IS NOT A VALID FIELD CODE
 L62 219 FILE MEDLINE
 L63 272 FILE CAPLUS
 L64 260 FILE BIOSIS
 'IN' IS NOT A VALID FIELD CODE
 L65 166 FILE EMBASE
 L66 31 FILE WPIDS
 L67 0 FILE JICST-EPLUS

TOTAL FOR ALL FILES
 L68 948 WHALEN, J?/AU, IN OR WHALEN J?/AU, IN

=> s 154 and 161 and 168
 L69 0 FILE MEDLINE
 L70 0 FILE CAPLUS
 L71 0 FILE BIOSIS
 L72 0 FILE EMBASE
 L73 0 FILE WPIDS
 L74 0 FILE JICST-EPLUS

TOTAL FOR ALL FILES
 L75 0 L54 AND L61 AND L68

=> s (154 or 161 or 168) and (110 or 117 or 124)
 L76 0 FILE MEDLINE
 L77 0 FILE CAPLUS
 L78 0 FILE BIOSIS
 L79 0 FILE EMBASE
 L80 0 FILE WPIDS
 L81 0 FILE JICST-EPLUS

TOTAL FOR ALL FILES
 L82 0 (L54 OR L61 OR L68) AND (L10 OR L17 OR L24)

=> del his y

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL